Guest Editor(s)
Prof. Dr. Ondřej Fiala
Email: fiala.o@centrum.cz
Affiliation: Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
Homepage:
Research Interests: urological malignancies, colorectal cancer, targeted therapy, immunotherapy, biomarkers
Dr. Radka Vaclavikova
Email: radka.vaclavikova@szu.gov.cz
Affiliation: Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic
Homepage:
Research Interests: solid tumors, genetic and transcriptomic profiles, molecular biomarkers, prognosis
Summary
Renal cell carcinoma (RCC) remains one of the most rapidly evolving fields in oncology, driven by advances in immunotherapy, targeted therapies, and biomarker research. Despite significant improvements in patient outcomes, substantial challenges remain in identifying predictive and prognostic biomarkers, understanding mechanisms of treatment response and resistance, and optimizing patient selection for emerging therapeutic strategies.
This Special Issue aims to highlight recent advances in biomarkers, immunotherapy, and precision treatment approaches in RCC. We welcome original research articles, reviews, and translational studies addressing molecular and immune biomarkers, tumor microenvironment characterization, mechanisms of therapeutic response and resistance, novel immunotherapeutic and targeted treatment strategies, as well as integrative genomic, transcriptomic, proteomic, metabolomic, and other omics-based approaches with potential clinical relevance. Particular emphasis will be placed on studies that improve biological understanding of RCC and support the development of personalized treatment strategies.
Keywords
renal cell carcinoma, biomarkers, precision oncology, personalized medicine, tumor microenvironment, prognostic biomarkers, immune checkpoint inhibitors, genomics, multi-omics, translational research, precision treatment
Login
Register
Submit a Paper
Propose a Special lssue